Localized Prostate Cancer VL

DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer”. Dr. Wallis discusses DNA damage repair mutations and how they present in men with localized prostate cancer. They also discuss the specific genomic mutations seen most commonly in men with DNA damage repair mutations affecting their prosta...

The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider

Details
Masoom Haider, a presenter at the 2022 AdMeTech Global Summit for Prostate Cancer, joins Phillip Koo to discuss the upcoming 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer where he'll present on radiomics and machine learning. Dr. Haider provides a high level overview of radiomics and the potential there is within this field. In November 1997, AdMeTech Foundation was est...

Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy

Details
Peter Gann and Adam Murphy join Ashley Ross to discuss how the use of the Genomic Prostate Score (GPS) may intersect with patient health literacy to affect decision-making regarding prostate cancer treatment. The discussion begins with an overview of genomics in prostate cancer, particularly the lack of validation of the Oncotype DX assay on African American men. From there, the conversation then...

How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer

Details
Andrew Winer and Ashley Ross engage in conversation about critical questions surrounding genomic testing and its impact on active surveillance and NCCN risk classification within the African American population. Dr. Winer points out that prostate cancer transforms into more clinically significant disease, grows faster, and often metastasizes earlier in African American men versus Caucasian men. He...

The ENACT Trial: Ezalutamide Monotherapy plus Active Surveillance vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Prostate Cancer - Neal Shore

Details
Neal Shore joins Alicia Morgans in a discussion on the ENACT Randomized Clinical Trial investigating the use of enzalutamide in prostate cancer patients who are starting on active surveillance (AS). They discuss the purpose of the study and Dr. Shore details the study design. There are few published studies prospectively assessing pharmacological interventions that may delay prostate cancer progre...

LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen

Details
At the 2022 EAU meeting, Declan Murphy presented the initial results of LuTectomy, a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to radical prostatectomy. Biochemical recurrence rates remain very high for men undergoing either surgery or radiotherapy for localized prostate cancer and no neoadjuvant strategies have succeeded this far in changing that. In...

Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin

Details
Daniel Lin joins Alicia Morgans in highlighting a guideline-directed practical course on how to use genomics in clinical practice. Dr. Lin was part of the instructional course faculty at the AUA annual meeting. The learning objectives of this course include a discussion on the research studies that led to the approval of genomic testing for prostate cancer, ordering appropriate genomic testing bas...

Genomic Risk Classification in Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Alicia Morgans in a conversation on genomic risk classification in localized prostate cancer. They discuss the risk stratification of prostate cancer and where the use of this is most valuable. Dr. Cooperberg highlights this topic in terms of two basic categories of markers: the pre-diagnostic in terms of liquid tests and post-diagnostic settings. Biographies: Matthew Coop...

Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas

Details
Daniel Barocas joins Alicia Morgans in a conversation on the prospective population-based Comparative Effectiveness Analysis of Surgery And Radiation (CEASAR) study which assess rates and predictors of patient-reported treatment regret among men deciding on treatment for localized prostate cancer. The CEASAR Study began accruing patients in 2010 and has a population-based cohort of almost 3000 men...

Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz

Details
Laurence Klotz joins Phillip Koo at the 13th International Uro-Oncology Congress in São Paulo, Brazil in a discussion on Active Surveillance (AS), High-intensity focused ultrasound (HIFU), and focal therapy in Latin America and developing countries. There are challenges with active surveillance in developing countries that might not have formal prostate cancer screening programs, a lack of resourc...
email news signup